Marshall Wace, LLP Relay Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 27,768 shares of RLAY stock, worth $94,688. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,768
Previous 1,405,714
98.02%
Holding current value
$94,688
Previous $9.95 Million
98.85%
% of portfolio
0.0%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding RLAY
# of Institutions
207Shares Held
159MCall Options Held
100KPut Options Held
26.8K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$95.2 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA15MShares$51.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$36 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY8.95MShares$30.5 Million3.17% of portfolio
-
Tang Capital Management LLC San Diego, CA8.07MShares$27.5 Million2.5% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $410M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...